➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
AstraZeneca
Harvard Business School
McKinsey
Merck
Mallinckrodt

Last Updated: September 23, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ABEMACICLIB

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Abemaciclib

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01394016 ↗ A Phase 1 Study of LY2835219 In Participants With Advanced Cancer Active, not recruiting Eli Lilly and Company Phase 1 2009-12-01 The purpose of this study is to determine a safe dose of LY2835219 to be given to participants with advanced cancer and to determine any side effects that may be associated with LY2835219 in this population. Efficacy measures will be used to assess the activity of LY2835219 in this population.
NCT01739309 ↗ Study of LY2835219 for Mantle Cell Lymphoma Active, not recruiting Eli Lilly and Company Phase 2 2013-03-01 The purpose of this study is to estimate the disease control rate with LY2835219 for relapsed or refractory mantle cell lymphoma.
NCT01913314 ↗ A Study of ^14C-LY2835219 in Healthy Participants Completed Eli Lilly and Company Phase 1 2013-08-01 This type of study is called a radiolabeled study. For this study, LY2835219 (study drug) has been specially prepared to contain radiolabeled carbon [14C]. [14C] is a naturally occurring radioactive form of the element carbon. This study will help understand how the drug appears in the blood, urine, and stool after it is administered. In addition, this study will also evaluate the safety and tolerability of a single dose of LY2835219 when given to healthy participants. Information about any side effects that may occur will also be collected. This study will last about 3 weeks for each participant, not including screening.
NCT02014129 ↗ A Study of LY2835219 in Japanese Participants With Advanced Cancer Active, not recruiting Eli Lilly and Company Phase 1 2013-12-01 The main purpose of this study is to evaluate safety and side effects of LY2835219 in Japanese participants with advanced cancer.
NCT02057133 ↗ A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread Recruiting Eli Lilly and Company Phase 1 2014-03-01 The main purpose of this study is to evaluate the safety of a study drug known as LY2835219 in combination with different therapies (letrozole, anastrozole, tamoxifen, exemestane, exemestane plus everolimus, trastuzumab, or LY3023414 plus fulvestrant) for breast cancer that has spread to other parts of the body.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Abemaciclib

Condition Name

Condition Name for Abemaciclib
Intervention Trials
Breast Cancer 16
Metastatic Breast Cancer 10
Breast Neoplasms 6
Advanced Cancer 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Abemaciclib
Intervention Trials
Breast Neoplasms 49
Neoplasms 16
Carcinoma 12
Neoplasm Metastasis 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Abemaciclib

Trials by Country

Trials by Country for Abemaciclib
Location Trials
United States 386
Spain 41
Germany 23
France 21
Australia 21
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Abemaciclib
Location Trials
Massachusetts 30
Texas 28
California 26
New York 21
Florida 19
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Abemaciclib

Clinical Trial Phase

Clinical Trial Phase for Abemaciclib
Clinical Trial Phase Trials
Phase 4 3
Phase 3 11
Phase 2 59
[disabled in preview] 48
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Abemaciclib
Clinical Trial Phase Trials
Not yet recruiting 79
Recruiting 33
Completed 8
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Abemaciclib

Sponsor Name

Sponsor Name for Abemaciclib
Sponsor Trials
Eli Lilly and Company 76
National Cancer Institute (NCI) 15
Dana-Farber Cancer Institute 9
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Abemaciclib
Sponsor Trials
Industry 99
Other 79
NIH 15
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Colorcon
McKinsey
Merck
Express Scripts
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.